Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-000076-28 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort A: Alectinib 600 Milligrams (mg) | Experimental | This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death. Enrollment to Cohort A is complete. |
|
| Cohort B: Dose Finding Phase (DFP) Alectinib | Experimental | This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose. Enrollment to Cohort B is complete. |
|
| Cohort B: Dose Expansion Phase (DEP) Alectinib | Experimental | This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death. Enrollment to Cohort B is complete. |
|
| Cohort C: Atezolizumab 1200 mg | Experimental | This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death. Enrollment to Cohort C is complete. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Alectinib | Drug | Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death. |
| Measure | Description | Time Frame |
|---|---|---|
| Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Baseline up to disease progression or death (up to approximately 6 years) | |
| Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) | |
| Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1 | Baseline up to disease progression or death (up to approximately 6 years) | |
| Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) | |
| Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1 | Month 12 | |
| Cohort F: Investigator-Assessed Objective Response Rate (ORR) Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) | |
| Cohort G: Incidence of Adverse Events (AEs) | Baseline to last dose of study treatment + 30 days or until initiation of new anticancer therapy, whichever occurs first (up to approximately 6 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Cohorts A-F: Duration of Response (DOR) as Assessed by the Investigator Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) | |
| Cohorts A, B and D: Percentage of Participants with Clinical Benefit Response as Assessed by the Investigator Based on RECIST v1.1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UC Davis | Sacramento | California | 95817 | United States | ||
| Rocky Mountain Cancer Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40525978 | Derived | Mayerhoefer ME, Kienzle A, Woo S, Vargas HA. Update on Liquid Biopsy. Radiology. 2025 Jun;315(3):e241030. doi: 10.1148/radiol.241030. | |
| 38898120 | Derived | Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. Nat Med. 2024 Jul;30(7):1923-1932. doi: 10.1038/s41591-024-03008-4. Epub 2024 Jun 19. |
Not provided
Not provided
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Cohort C: Pemetrexed, Cisplatin or Carboplatin | Active Comparator | This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care. Enrollment to Cohort C is complete. |
|
| Cohort C: Gemcitabine, Cisplatin or Carboplatin | Active Comparator | This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D. Enrollment to Cohort C is complete. |
|
| Cohort D: Entrectinib 600 Milligrams (mg) | Experimental | This cohort includes participants with c-ros oncogene 1 positive (ROS1+) NSCLC. Participants will receive entrectinib 600 mg orally once a day (QD) until disease progression, unacceptable toxicity, withdrawal of consent or death. Enrollment to Cohort D is complete. |
|
| Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib | Experimental | This cohort includes participants with BRAF V600 mutation. Participants will receive: atezolizumab 1680 mg IV Q4W after the run-in period; cobimetinib 60 mg orally (PO) QD on Days 1-21 of each cycle during the run-in and triple-combination periods; and vemurafenib 960 mg PO twice daily (BID) on Days 1-21 of the initial run-in period, then 720 mg PO BID on Days 1-22 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period. Enrollment to Cohort E is complete. |
|
| Cohort F: Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed | Experimental | This cohort includes participants with EGFR exon 20+ NSCLC. Participants will receive atezolizumab + bevacizumab + carboplatin + pemetrexed for 4 or 6 induction cycles (cycle = 21 days). After induction therapy, participants will continue maintenance treatment with atezolizumab + bevacizumab + pemetrexed until disease progression, unacceptable toxicity, withdrawal of consent, or death. Enrollment to Cohort F is complete. |
|
| Cohort G: Divarasib or Docetaxel | Experimental | Experimental: Cohort G: GDC-6036 or Docetaxel This cohort includes participants with KRAS G12C mutation. Participants will receive GDC-6036 PO QD or IV docetaxel Q3W (75 mg/m^2) until disease progression or unacceptable toxicity New participants will no longer receive docetaxel. |
|
| Cohort Z: Natural History Cohort | No Intervention | Participants with genomic profiles of interest that are not enrolled in the other cohorts will enter into natural history follow-up. |
|
| Atezolizumab | Drug | Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E). |
|
|
| Pemetrexed | Drug | Participants will receive pemetrexed 500 mg/m^2 IV infusion on Day 1 Q21D. |
|
| Cisplatin | Drug | Participants will receive cisplatin 75 mg/m^2 IV on Day 1 Q21D. |
|
| Carboplatin | Drug | Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D. |
|
| Gemcitabine | Drug | Participants will receive gemcitabine 1000 or 1250 mg/m^2 on Days 1 and 8 of every cycle (1 Cycle=21 days). |
|
| Entrectinib | Drug | Participants will receive entrectinib 600 mg orally QD. |
|
|
| Cobimetinib | Drug | Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods. |
|
|
| Vemurafenib | Drug | Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period. |
|
|
| Bevacizumab | Drug | Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods. |
|
|
| Divarasib | Drug | Participants will receive divarasib PO QD until disease progression or unacceptable toxicity. |
|
|
| Docetaxel | Drug | Participants will receive IV docetaxel Q3W (75 mg/m^2) until disease progression or unacceptable toxicity |
|
| Baseline up to disease progression or death (up to approximately 6 years) |
| Cohorts A, B, D, F: PFS as Assessed by the Investigator Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) |
| Cohorts A-F: Duration of Response as Assessed by the Independent Review Facility (IRF) Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) |
| Cohorts A, B and D: Percentage of Participants with Clinical Benefit Response as Assessed by IRF Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) |
| Cohorts A-F: PFS as Assessed by IRF Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) |
| Cohorts A-F: Percentage of Participants with Confirmed Objective Response as Assessed by IRF Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) |
| Cohorts A-F: Overall Survival (OS) | Baseline up to approximately 6 years |
| Cohorts A-F: Percentage of Participants with Adverse Events (AEs) | Baseline up to approximately 6 years |
| Cohorts A, B, D, E, F: Percentage of Participants with Improvement Compared with Baseline in Total Severity Symptom Score as Measured by Symptoms in Lung Cancer (SILC) Scale in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain) | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohorts A-F: Time to Deterioration in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain) as Measured by the SILC Scale | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohorts C, E, F: Change from Baseline in Patient-Reported Lung Cancer Symptom (Cough, Dyspnea, Chest pain) Score as Measured by the SILC Scale | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohorts A-F: Change from Baseline in Health Related Quality of Life (HRQoL) Scores as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30) | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohorts A, B, D, E, F: Change from Baseline in HRQoL Scores as Measured by the SILC Scale | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohorts A-F: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the EORTC QLQ-C30 | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohorts A, B, D, E, F: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the SILC Scale | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohorts A-F: Health Status Assessed as an Index Score Using the European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Questionnaire | Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years |
| Cohort B: Percentage of Participants with Dose-Limiting Toxicities (DLTs) | Day 1 to Day 28 of Cycle 1 (cycle length = 28 days) |
| Cohort B: Maximum Plasma Concentration (Cmax) of Alectinib | DFP: Dose-Finding Phase; DEP: Dose-Expanding Phase. | DFP: pre-dose (0 hours [hr]) on Day 1 of Cycle 2; 0.5, 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days) |
| Cohort B: Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of Alectinib | DFP: pre-dose (0 hr) on Day 1 of Cycle 2; 0.5, 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days) |
| Cohort B: Time to Reach Cmax (Tmax) of Alectinib | DFP: pre-dose (0 hr) on Day 1 of Cycle 2; 0.5, 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days) |
| Cohort B: Half-Life (t1/2) of Alectinib | DFP: pre-dose (0 hr) on Day 1 of Cycle 2; 0.5, 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days) |
| Cohort B: Metabolite to Parent Exposure Ratio for AUC0-last | DFP: pre-dose (0 hr) on Day 1 of Cycle 2; 0.5, 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days) |
| Cohort B: Metabolite to Parent Exposure Ratio for Cmax | DFP: pre-dose (0 hr) on Day 1 of Cycle 2; 0.5, 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days) |
| Cohort C: Percentage of Participants with Objective Response as Assessed by the Investigator Based on RECIST v1.1 | Baseline up to disease progression or death (up to approximately 6 years) |
| Cohort C: Percentage of Participants Free from Disease Progression as Assessed by the Investigator Based on RECIST v1.1 at Months 6 and 12 | Months 6, 12 |
| Cohort C: PFS as Assessed by the Investigator based on RECIST v1.1 in bTMB PP2 | Baseline up to disease progression or death (up to approximately 6 years) |
| Cohort C: OS in bTMB PP2 | Baseline up to approximately 6 years |
| Cohort D: Time to CNS progression as Assessed by the Investigator Based on RECIST v1.1 | Baseline up to CNS progression (up to approximately 6 years) |
| Cohort D: Time to CNS progression as Assessed by the IRF Based on RECIST v1.1 | Baseline up to CNS progression (up to approximately 6 years) |
| Cohort D: Percentage of Participants who have shown improvement compared with Baseline in patient-reported cognitive function, fatigue, HRQoL, headache and vision disorder per the EORTC QLQ-C30 | Baseline, every 4 weeks until disease progression, up to approximately 6 years |
| Cohort D: Percentage of Participants who have shown improvement compared with Baseline in patient-reported cognitive function, fatigue, HRQoL, headache and vision disorder per the EORTC QLQ-BN20 | Baseline, every 4 weeks until disease progression, up to approximately 6 years |
| Cohort D: Mean Plasma Concentration of Entrectinib | Pre-dose (0 hr), 1.5 and 4 hr post-dose on Day 1 of Cycles 1, 2, 3, 4 and 5; and pre-dose on Day 1 of each subsequent treatment cycle (1 cycle = 28 days). |
| Cohort D: Mean Plasma Concentration of Entrectinib Metabolite M5 | Pre-dose (0 hr), 1.5 and 4 hr post-dose on Day 1 of Cycles 1, 2, 3, 4 and 5; and pre-dose on Day 1 of each subsequent treatment cycle (1 cycle = 28 days). |
| Cohort E: TIR as Assessed by the Investigator Based on RECIST v1.1 | Month 9 |
| Cohort E: TIR as Assessed by IRF | Month 12 |
| Cohorts E, F: Serum Concentration of Atezolizumab | Pre-dose (0 hr), 1.5 and 4 hr post-dose on Day 1 of Cycles 1, 2, 3, 4 and 5; and pre-dose on Day 1 of each subsequent treatment cycle (1 cycle = 28 days) |
| Cohorts E, F: Change from Baseline in Anti-Drug Antibodies (ADAs) | Baseline up to approximately 6 years |
| Cohorts E, F: Time to Confirmed Deterioration (TTCD) in Participant-Reported Lung Cancer Symptoms of Cough, Dyspnea, and Chest Pain, as Measured by the Symptoms in Lung Cancer (SILC) | Baseline up to approximately 6 years |
| Cohorts E, F: Proportion of Participants who Improve Compared with Baseline in Participant-Reported Lung Cancer Symptoms of Cough, Dyspnea, and Chest Pain, as Measured by the SILC | Baseline up to approximately 6 years |
| Cohort G: Plasma Concentration of Divarasib | Baseline up to approximately 6 years |
| Denver |
| Colorado |
| 80218 |
| United States |
| SCRI Florida Cancer Specialists South | Fort Myers | Florida | 33901 | United States |
| Florida Cancer Specialist, North Region | St. Petersburg | Florida | 33705 | United States |
| University of Kentucky | Lexington | Kentucky | 40536 | United States |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | United States |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | United States |
| Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York | 10021 | United States |
| Montefiore Medical Center | The Bronx | New York | 10461 | United States |
| Oregon HSU | Portland | Oregon | 97210 | United States |
| St. Luke's University Health network | Bethlehem | Pennsylvania | 18015 | United States |
| Sarah Cannon Research Institute / Tennessee Oncology | Chattanooga | Tennessee | 37404 | United States |
| Fundación CENIT para la Investigación en Neurociencias | Buenos Aires | C1125ABD | Argentina |
| Hospital Italiano | Buenos Aires | C1181ACH | Argentina |
| Hospital Britanico de Buenos Aires | Ciudad Autonoma Buenos Aires | C1284AEB | Argentina |
| Royal North Shore Hospital | St Leonards | New South Wales | 2065 | Australia |
| The Prince Charles Hospital | Chermside | Queensland | 4032 | Australia |
| Ashford Cancer Center Research | Kurralta Park | South Australia | 5037 | Australia |
| UZ Brussel | Brussels | 1090 | Belgium |
| Cliniques Universitaires St-Luc | Brussels | 1200 | Belgium |
| UZ Leuven Gasthuisberg | Leuven | 3000 | Belgium |
| Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda | Ijuí | Rio Grande do Sul | 98700-000 | Brazil |
| Hospital Sao Lucas - PUCRS | Porto Alegre | Rio Grande do Sul | 90610-000 | Brazil |
| Instituto do Cancer do Estado de Sao Paulo - ICESP | São Paulo | São Paulo | 01246-000 | Brazil |
| Instituto Nacional de Cancer - INCa | Rio de Janeiro | 20560-120 | Brazil |
| Cross Cancer Institute | Edmonton | Alberta | T6G 1Z2 | Canada |
| CancerCare Manitoba | Winnipeg | Manitoba | R3E 0V9 | Canada |
| Royal Victoria Regional Health Centre | Barrie | Ontario | L4M 6M2 | Canada |
| William Osler Health System Brampton Civic Hospital | Brampton | Ontario | L6R 3J7 | Canada |
| London Health Sciences Centre · Victoria Hospital | London | Ontario | N6A 5W9 | Canada |
| Lakeridge Health Center | Oshawa | Ontario | L1G 2B9 | Canada |
| Sunnybrook Health Sciences Centre | Toronto | Ontario | M4N 3M5 | Canada |
| Princess Margaret Cancer Center | Toronto | Ontario | M5G 1Z5 | Canada |
| Jewish General Hospital | Montreal | Quebec | H3T 1E2 | Canada |
| IUCPQ (Hôpital Laval) | Québec | Quebec | G1V 4G5 | Canada |
| Saskatoon Cancer Centre | Saskatoon | Saskatchewan | SK S7N 4H4 | Canada |
| Bradford Hill Centro de Investigaciones Clinicas | Recoleta | 8420383 | Chile |
| Beijing Cancer Hospital | Beijing | 100142 | China |
| Jilin Cancer Hospital | Changchun | 132013 | China |
| Hunan Cancer Hospital | Changsha | 410013 | China |
| The second Xiangya hospital of central south university | Changsha | 410100 | China |
| Sichuan Cancer Hospital | Chengdu | 610041 | China |
| West China Hospital - Sichuan University | Chengdu | 610047 | China |
| The First Affiliated Hospital of Guangzhou Medical University Pharmacy | Guangzhou | 510120 | China |
| Zhejiang Cancer Hospital | Hangzhou | 310022 | China |
| Shandong Cancer Hospital | Jinan | 250117 | China |
| The Second Affiliated Hospital to Nanchang University | Nanchang | 330006 | China |
| Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School | Nanjing | 210008 | China |
| Fudan Unviversity Shanghai Cancer Center | Shanghai | 200032 | China |
| First Affiliated Hospital of Medical College of Xi'an Jiaotong University | Xi'an | 710061 | China |
| Institut Bergonie CLCC Bordeaux | Bordeaux | 33000 | France |
| Centre Francois Baclesse | Caen | 14076 | France |
| Centre Oscar Lambret | Lille | 59020 | France |
| Centre Léon Bérard | Lyon | 69373 | France |
| Hopital Caremeau | Nîmes | 30029 | France |
| Hopital Robert Schuman | Nouilly | 57645 | France |
| Hôpital Européen Georges Pompidou | Paris | 75908 | France |
| Hopital Tenon | Paris | 75970 | France |
| CHU Poitiers | Poitiers | 86021 | France |
| Hopital Pontchaillou | Rennes | 35033 | France |
| CHU de Toulouse - Hôpital Larrey | Toulouse | 31059 | France |
| Klinikum Chemnitz gGmbH | Chemnitz | 09116 | Germany |
| Asklepios-Fachklinik Muenchen-Gauting | Gauting | 82131 | Germany |
| Thoraxklinik Heidelberg gGmbH | Heidelberg | 69126 | Germany |
| HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed | Wiesbaden | 65199 | Germany |
| Queen Mary Hospital | Hong Kong | Hong Kong |
| Prince of Wales Hosp | Shatin | Hong Kong |
| Soroka Medical Center | Beersheba | 8410101 | Israel |
| Rambam Health Care Campus | Haifa | 3109601 | Israel |
| Meir Medical Center | Kfar Saba | 4428164 | Israel |
| Rabin MC | Petah Tikva | 4941492 | Israel |
| Chaim Sheba Medical Center | Ramat Gan | 5262100 | Israel |
| Sourasky / Ichilov Hospital; Dept. of Oncology | Tel Aviv | 6423906 | Israel |
| Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale | Naples | Campania | 80131 | Italy |
| IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola | Meldola | Emilia-Romagna | 47014 | Italy |
| Irccs Centro Di Riferimento Oncologico (CRO) | Aviano | Friuli Venezia Giulia | 33081 | Italy |
| Azienda Ospedaliera San Camillo Forlanini | Rome | Lazio | 00151 | Italy |
| Asst Papa Giovanni XXIII | Bergamo | Lombardy | 24128 | Italy |
| ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona | Cremona | Lombardy | 26100 | Italy |
| Irccs Istituto Europeo di Oncologia (IEO) | Milan | Lombardy | 20141 | Italy |
| Asst Di Monza | Monza | Lombardy | 20900 | Italy |
| Azienda Sanitaria Ospedaliera S Luigi Gonzaga | Orbassano (TO) | Piedmont | 10043 | Italy |
| Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital | Bunkyō City | 113-8677 | Japan |
| National Hospital Organization Kyushu Medical Center | Fukuoka | 810-8563 | Japan |
| National Hospital Organization Kyushu Cancer Center | Fukuoka | 811-1395 | Japan |
| Kyushu University Hospital | Fukuoka | 812-8582 | Japan |
| Hiroshima University Hospital | Hiroshima | 734-8551 | Japan |
| Kanazawa University Hospital | Ishikawa | 920-8641 | Japan |
| Kanagawa Cancer Center | Kanagawa | 241-8515 | Japan |
| University Hospital Kyoto Prefectural University of Medicine | Kyoto | 602-8566 | Japan |
| Shikoku Cancer Center | Matsuyama | 791-0280 | Japan |
| Tohoku University Hospital | Miyagi | 980-8574 | Japan |
| Sendai Kousei Hospital | Miyagi | 981-0914 | Japan |
| Niigata University Medical & Dental Hospital | Niigata | 951-8520 | Japan |
| Niigata Cancer Center Hospital | Niigata | 951-8566 | Japan |
| Kindai University Hospital | Osaka | 589-8511 | Japan |
| Saga University Hospital | Saga | 849-8501 | Japan |
| Shizuoka Cancer Center | Shizuoka | 411-8777 | Japan |
| Juntendo University Hospital | Tokyo | 113-8431 | Japan |
| The Cancer Institute Hospital of JFCR | Tokyo | 135-8550 | Japan |
| Kyorin University Hospital | Tokyo | 181-8611 | Japan |
| Fujita Health University Hospital | Toyoake-shi | 470-1192 | Japan |
| Wakayama Medical University Hospital | Wakayama | 641-8510 | Japan |
| National Hospital Organization Yamaguchi - Ube Medical Center | Yamaguchi | 775-0241 | Japan |
| Hospital Angeles Tijuana | Tijuana | Estado de Baja California | 22010 | Mexico |
| Health Pharma Professional Research | Mexico City | Mexico CITY (federal District) | 03100 | Mexico |
| AVIX Investigación Clínica S.C | Monterrey | Nuevo León | 64710 | Mexico |
| Oncologico Potosino | San Luis Potosí City | San Luis Potosí | 78250 | Mexico |
| Auckland City Hospital | Auckland | 1023 | New Zealand |
| Hemato Oncología de Panamá Especializada | Panama City | 0801 | Panama |
| Hospital Nacional Edgardo Rebagliati Martins | Lima | 11 | Peru |
| Instituto Nacional de Enfermedades Neoplasicas | Lima | 15038 | Peru |
| Instituto Peruano de Oncología y Radioterapia | Lima | Peru |
| Clinica Ricardo Palma | San Isidro | Lima 27 | Peru |
| Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii | Gda?sk | 80-214 | Poland |
| Krakowski Szpital Specjalistyczny im sw.Jana Pawla II | Krakow | 31-202 | Poland |
| Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie | Olsztyn | 10-357 | Poland |
| Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy | Otwock | 05-400 | Poland |
| Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu | Poznan | 60-569 | Poland |
| Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie | Warsaw | 02-781 | Poland |
| Moscow City Oncology Hospital #62 | Moscovskaya Oblast | Moscow Oblast | 143423 | Russia |
| Principal Military Clinical Hospital n.a. N.N. Burdenko | Moscow | Moscow Oblast | 105229 | Russia |
| S-Pb clinical scientific practical center of specialized kinds of medical care (oncological) | Saint Petersburg | Sankt-Peterburg | 197758 | Russia |
| Clinical Oncology Dispensary | Omsk | 644013 | Russia |
| Clinical Center of Serbia | Belgrade | 11000 | Serbia |
| University Hospital Medical Center Bezanijska kosa | Belgrade | 11080 | Serbia |
| Institute for Pulmonary Diseases of Vojvodina | Kamenitz | 21204 | Serbia |
| Clinical Center Nis | Niš | 18000 | Serbia |
| National University Hospital | Singapore | 119228 | Singapore |
| National Cancer Centre | Singapore | 169610 | Singapore |
| National Cancer Center | Gyeonggi-do | 10408 | South Korea |
| Chonnam National University Hwasun Hospital | Jeollanam-do | 58128 | South Korea |
| Seoul National University Hospital | Seoul | 03080 | South Korea |
| Asan Medical Center | Seoul | 05505 | South Korea |
| Yonsei University Health System/Severance Hospital | Seoul | 120-752 | South Korea |
| Insititut Catala D'Oncologia | L'Hospitalet de Llobregat | Barcelona | 08908 | Spain |
| Complejo Hospitalario Universitario de Santiago (CHUS) | Santiago de Compostela | LA Coruna | 15706 | Spain |
| Clinica Universitaria de Navarra | Pamplona | Navarre | 31008 | Spain |
| Hospital General Univ. de Alicante | Alicante | 03010 | Spain |
| Hospital Universitari Vall d'Hebron | Barcelona | 08035 | Spain |
| Hospital Clínic i Provincial | Barcelona | 08036 | Spain |
| ICO Badalona - Hospital Germans Trias i Pujol | Barcelona | 08916 | Spain |
| Hospital General Universitario Gregorio Marañon | Madrid | 28007 | Spain |
| Hospital Ramon y Cajal | Madrid | 28034 | Spain |
| Hospital Universitario 12 de Octubre | Madrid | 28041 | Spain |
| Centro Integral Oncologico Clara Campal | Madrid | 28050 | Spain |
| Hospital Universitario Puerta de Hierro | Madrid | 28222 | Spain |
| Hospital Quiron de Madrid | Madrid | 28223 | Spain |
| Hospital Regional Universitario Carlos Haya | Málaga | 29010 | Spain |
| Hospital Universitario Virgen del Rocio | Seville | 41013 | Spain |
| Hospital Clínico Universitario de Valencia | Valencia | 46010 | Spain |
| Kaohsiung Chang Gung Memorial Hospital | Kaohsiung City | 83301 | Taiwan |
| National Taiwan Uni Hospital | Taipei | 100 | Taiwan |
| Taipei Veterans General Hospital | Taipei | 112 | Taiwan |
| Chang Gung Medical Foundation - Linkou | Taoyuan | 333 | Taiwan |
| Faculty of Med. Siriraj Hosp. | Bangkok | 10700 | Thailand |
| Prince of Songkla University | Hat Yai | 90110 | Thailand |
| Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology | Adana | 01230 | Turkey (Türkiye) |
| Akdeniz University Medical Faculty; Medical Oncology Department | Antalya | 07070 | Turkey (Türkiye) |
| Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department | Edirne | 22770 | Turkey (Türkiye) |
| Medipol University Medical Faculty; Oncology Department | Istanbul | 34214 | Turkey (Türkiye) |
| Marmara University Pendik Training and Research Hospital; Medikal Onkoloji | Istanbul | 34890 | Turkey (Türkiye) |
| Medikal Park Izmir Hospital | Kar??yaka | 35575 | Turkey (Türkiye) |
| Hacettepe Uni Medical Faculty Hospital; Oncology Dept | Sihhiye/Ankara | 06230 | Turkey (Türkiye) |
| 38190582 | Derived | Wang HY, Ho CC, Lin YT, Liao WY, Chen CY, Shih JY, Yu CJ. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. JCO Precis Oncol. 2024 Jan;8:e2300314. doi: 10.1200/PO.23.00314. |
| 35995953 | Derived | Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C582670 | alectinib |
| C000594389 | atezolizumab |
| D000068437 | Pemetrexed |
| D002945 | Cisplatin |
| D016190 | Carboplatin |
| D000093542 | Gemcitabine |
| C000607349 | entrectinib |
| C574276 | cobimetinib |
| D000077484 | Vemurafenib |
| D000068258 | Bevacizumab |
| D000077143 | Docetaxel |
| ID | Term |
|---|---|
| D006147 | Guanine |
| D007042 | Hypoxanthines |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D005971 | Glutamates |
| D024342 | Amino Acids, Acidic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000600 | Amino Acids, Dicarboxylic |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017672 | Nitrogen Compounds |
| D017671 | Platinum Compounds |
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
| D003841 | Deoxycytidine |
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D007211 | Indoles |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D004224 | Diterpenes |
| D013729 | Terpenes |
Not provided
Not provided